El interés en corto de Sagimet Biosciences da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Sagimet Biosciences. Los datos de interés en corto se actualizan cada dos semanas.

Sagimet Biosciences (NASDAQ:SGMT) Bolsa, Informe de interés en corto

Sagimet Biosciences

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences Inc

WIIM

BCTX

BriaCell Therapeutics shares are trading lower after the company announced a $5.13 million offering of shares and warrants priced at $0.975 per unit.

Wells Fargo analyst Timur Braziler maintains First Hawaiian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FHB#NASDAQ">FHB</a>) with a Underweight and lowers the price target from $22 to $20.

News

Price Target

Analyst Ratings

Wells Fargo Maintains Underweight on First Hawaiian, Lowers Price Target to $20

Wells Fargo analyst Timur Braziler maintains Western Alliance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAL#NYSE">WAL</a>) with a Equal-Weight and raises the price target from $85 to $92.

Wells Fargo Maintains Equal-Weight on Western Alliance, Raises Price Target to $92

Interest rates determine the risk and reward perceptions of virtually all asset classes in the financial market. The benchmark for return is&mdash;and has always been&mdash;the United States ten-year treasury bond yield, so when bond yields are high, investors tend to avoid higher-risk assets like stocks, as the risk is not worth it compared to bond yields.
Now that the Federal Reserve (the Fed) has lowered interest rates by the most since 2007, investors may think that lower returns could be ahead, especially now that the S&amp;P 500 has priced in most&mdash;if not all&mdash;of the potential effects these interest rate cuts have on the economy. Understanding that new money will shift into different market areas is key. Still, it all begins with knowing what interest rates will do in the coming quarters.
Sectors that typically have higher debts on their balance sheets are poised to benefit from lower interest rates. Lower interest expenses on that debt would drive up net income and earnings per share (EPS). For this reason, investors can find higher returns in sectors like consumer discretionary and the real estate sector.
<h2>Top Consumer Discretionary Stocks Poised for Higher Growth Ahead</h2>
This is one sector that could benefit from a double tailwind as interest rates work their way through the economy. Still, not all consumer discretionary stocks are made equal. This is going to be the case, especially for those with a smaller market capitalization and higher debt.
<h3>Analysts Expect Abercrombie&#39;s EPS to Jump 14.5% by 2025</h3>
Fitting this list, investors can see stocks like Abercrombie &amp; Fitch Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/anf#NYSE">ANF</a>), with its $7.3 billion market capitalization today, carrying over 73% debt to equity on its balance sheet. This makes the company a prime target for an EPS expansion name, as lower interest rates help both consumer trends and lower interest expenses.
Wall Street knows this is the case, as analysts at Jefferies Financial Group see up to $220 as a price target for the company, calling for a net upside of 53.3% from where the stock trades today. More than that, Wall Street analysts expect to see EPS of $2.86 for the end of 2025, a jump of 14.5% from today&#39;s EPS of $2.5 in Abercrombie &amp; Fitch.
This growth in EPS and the higher valuation are driven by both the company&#39;s small size and the potential earnings expansion that can come from lowering interest expenses to push EPS higher to a point where current forecasts might be on the conservative side.
<h3>Chewy&#39;s Debt and Size Make It a Prime Target for Future Gains</h3>
Another name that is worth mentioning for a potential buy in this trend is Chewy Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/chwy#NYSE">CHWY</a>) as a part of the consumer discretionary space with a healthy mix of consumer staples in the way that pet owners will always have room in their budgets to take care of their pets&#39; needs.
Because the company is only $12.6 billion in size and carries over 100% in debt compared to equity, it makes for a nearly perfect buy target in the coming quarters. This is why analysts at Piper Sandler see a price target on the stock of up to $35 a share, calling for a net upside potential of 16.3% from where it trades today.
More than that, bearish traders decided to trim their views on Chewy stock, as the short interest has declined by 2% over the past month alone to show capitulation from the bearish side of the market and opening room for bulls to take their places instead.
Among these bulls were Truist Financial and B. Riley Wealth Advisors, who boosted their holdings in Chewy stock by 39.3% and 74% as of August 2024. This would bring their net investments up to $2.5 million and $565,000 today.
<h2>Real Estate Stocks Poised for Growth Ahead of the Market</h2>
<h3>Healthpeak&#39;s Dividend and Growth Potential Make It a Standout REIT</h3>
Real estate stocks fit this same category. Because they need to acquire property and boost rental income, stocks like&nbsp;Healthpeak Properties Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/doc#NYSE">DOC</a>) shine. This $15.9 billion real estate investment trust (REIT) operates in the healthcare sector, an underrated growth source in the U.S. economy.
Wall Street analysts know that lower interest rates can help this company acquire more property and boost its bottom-line earnings, so Evercore decided to raise its price target to $26 a share for Healthpeak Properties. To prove these targets right, the stock must rally by as much as 15% from where it trades today.
Wall Street&#39;s earnings per share (EPS) forecasts are set at $0.44 a share for the next 12 months, up from today&#39;s $0.21 a share for a net 109.5% growth rate. This comes on top of one of the main benefits of investing in REITs: the dividend payout.
Healthpeak Properties offers a $1.2 payout for an annualized dividend yield of up to 5.3% to beat inflation and cushion any volatility that lower rates might bring into the market.
The article &quot;<a href="https://www.marketbeat.com/stock-ideas/lower-rates-higher-returns-key-stocks-to-watch-now/">Lower Rates, Higher Returns: Key Stocks to Watch Now</a>&quot; first appeared on MarketBeat.

Earnings

Large Cap

Mid Cap

REIT

Dividends

Markets

Trading Ideas

Real Estate

CHWY

Lower Rates, Higher Returns: Key Stocks to Watch Now

Phoenix Motor Says Determined The "Proterra Financial Statements" Is Incorrect

Cryptocurrency markets are trading lower amid escalating tensions in the Middle East.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$61,888.86&nbsp;&nbsp;</td>
<td>&nbsp;-2.5%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$2,498.87&nbsp;&nbsp;</td>
<td>&nbsp;-3.5%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>&nbsp;$147.33&nbsp;&nbsp;</td>
<td>&nbsp;-5%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.1074&nbsp;&nbsp;</td>
<td>&nbsp;-9%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00001633</td>
<td>-8.3%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul>
<li>IntoTheBlock data shows large transaction volume increased by around 99% and daily active addresses rose by 7.1%. Transactions greater than $100,000 are up from 5,655 to  9,193 in a single day. Exchanges netflows are down by 1,521.2%.</li>
<li>Coinglass data reports 159,405 traders were liquidated in the past 24 hours for $482.24 million, with crypto long liquidations of $361.8 million at the highest since Aug. 5. Bitcoin long liquidations of $90.7 million are at the highest level since Aug. 5.</li>
</ul>
Notable Developments:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41125099/ripple-receives-dubai-approval-for-blockchain-payment-services">Ripple Receives Dubai Approval For Blockchain Payment Services</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41122002/playbux-ceo-envisions-web3-future-where-crypto-is-earned-via-gaming-shopping">Playbux CEO Envisions Web3 Future Where Crypto Is Earned Via Gaming, Shopping</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41120425/arthur-hayes-cites-money-printing-as-key-factor-for-bitcoin-becoming-the-best-performing-a">Arthur Hayes Cites &#8216;Money Printing&#8217; As Key Factor For Bitcoin Becoming The &#8216;Best Performing Asset&#8217; In History</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41111755/robinhood-markets-launches-crypto-transfers-in-europe-enabling-bitcoin-ethereum-and-solana">Robinhood Markets Launches Crypto Transfers In Europe, Enabling Bitcoin, Ethereum, And Solana Transactions With 1% Deposit Match For A Limited Time</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41114110/the-dollar-is-weakening-heres-why-that-could-be-good-for-bitcoin-10x-research">The Dollar Is Weakening—Here&#8217;s Why That Could Be Good For Bitcoin: 10x Research</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41109127/asias-microstrategy-metaplanet-grabs-107-additional-bitcoins-to-boost-portfolio-by-nearly-">&#8216;Asia&#8217;s MicroStrategy&#8217; Metaplanet Boosts Portfolio With Fresh Acquisition Of 107 Bitcoins Worth Nearly $7M</a></li>
</ul>
Top Losers:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Arweave (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">AR</a>)</td>
<td>&nbsp;$19.67</td>
<td>&nbsp;-15.7%</td>
</tr>
<tr>
<td>Gala (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">GALA</a>)</td>
<td>&nbsp;$0.02032&nbsp;&nbsp;</td>
<td>&nbsp;-13.9%</td>
</tr>
<tr>
<td>Notcoin (CRYPTO: NOT)</td>
<td>&nbsp;$0.007543</td>
<td>&nbsp;-13.3%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: With Bitcoin prices retreating lower to $61,000, crypto trader Cold Blooded Shiller stated that even anything down into the green box represents opportunity for some of the best risk-reward long exposure to six-figure Bitcoin.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Do not forget, in the midset of the red candles that even anything down into the green box represents opportunity for some of the best risk-reward long exposure to 6-figure <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a>. <a href="https://t.co/AcMwgbZrFp">https://t.co/AcMwgbZrFp</a> <a href="https://t.co/IKf4GwQGB1">pic.twitter.com/IKf4GwQGB1</a>
&mdash; Cold Blooded Shiller (@ColdBloodShill) <a href="https://twitter.com/ColdBloodShill/status/1841170691556597971?ref_src=twsrc%5Etfw">October 1, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Crypto chart analyst Ali Martinez <a href="https://x.com/ali_charts/status/1841159390428115314">detailed</a> that Bitcoin has made a higher low and a higher high. He suggests the trend may have shifted from bearish to bullish.
Crypto trader Jelle compared the current Bitcoin price movement to its historical trends. He predicts new legs to start in October, "breaking out in the 2nd or 3rd week of the month."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">In the past bull-years, <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> has taken the summer to recharge, preparing for the next leg higher. All of those new legs higher started in October &#8211; breaking out in the 2nd or 3rd week of the month. I don&#39;t think this year is different. Final shakeout before new highs. <a href="https://t.co/CXEHhebEMU">pic.twitter.com/CXEHhebEMU</a>
&mdash; Jelle (@CryptoJelleNL) <a href="https://twitter.com/CryptoJelleNL/status/1841153285580878310?ref_src=twsrc%5Etfw">October 1, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Another crypto trader, IncomeSharks, <a href="https://x.com/IncomeSharks/status/1841173131572232524">believes</a> that if Bitcoin is able to re-test, "we continue back up."
What&#8217;s Next: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41119368/what-does-technical-analysis-say-about-bitcoin">What Does Technical Analysis Say About Bitcoin?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$GALA

$SHIB

$SOL

Bitcoin, Ethereum, Dogecoin Begin 'Uptober' Deep In The Red, But Traders See This As The 'Final Shakeout'

Ethereum Classic (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/etc/usd">ETC</a>) is trading lower by 6.2% to $18.50 during Tuesday&#8217;s session amid overall market weakness. Iran earlier launched a <a href="https://www.benzinga.com/news/global/24/10/41126038/iran-attacks-israel-with-missiles-middle-east-tensions-escalates-s-p-500-stocks-bitcoin-fall-as-oil">missile strike</a> against Israel, following the assassination of Hezbollah leader Hassan Nasrallah.
The attack, which saw between 100 to 200 missiles fired, marked a new escalation in regional tensions, with fears mounting over a broader conflict. In response, the United States bolstered its military presence, signaling the potential for further retaliatory action.
The sudden rise in conflict and uncertainty has rattled global markets, driving up safe-haven assets like gold and oil, while riskier assets such as cryptocurrencies took a hit.
Read Also: <a href="https://www.benzinga.com/news/24/10/41126631/hurricane-helene-devastation-the-latest-on-damage-companies-affected">Hurricane Helene Devastation: The Latest On Damage, Companies Affected</a>
What To Know: Cryptocurrencies, including Ethereum Classic, often see heightened volatility during periods of geopolitical unrest. As a smaller and more niche asset compared to Bitcoin or Ethereum, Ethereum Classic tends to be more vulnerable to sharp price movements during uncertain times. 
The growing conflict between Iran and Israel, with the involvement of the United States, has triggered widespread market anxiety. Investors, concerned about the potential impact on the global economy and energy markets, are fleeing riskier assets like ETC in favor of traditional safe-havens.
What Else: While Ethereum Classic has its own dedicated user base and unique blockchain infrastructure, it remains highly correlated with the broader cryptocurrency market. As political instability drives fear across global markets, investors are pulling back from cryptocurrencies as a whole.
Additionally, regulatory uncertainty around cryptocurrencies in regions like the U.S. and Europe, combined with the instability in the Middle East, is causing further trepidation among investors. 
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41122944/east-coast-dockworkers-strike-how-labor-dispute-impacts-economy-logistics-companies">East Coast Dockworkers Strike: How Labor Dispute Impacts Economy, Logistics Companies</a>

$ETC

Why Ethereum Classic Is Falling

The United Kingdom could generate between $4.38 billion and $12.6 billion annually in tax revenue by legalizing and regulating cannabis for adult use, according to a new <a href="https://clearmembers-uk.org/wp-content/uploads/2024/09/CLEAR-plan-V3.pdf">report</a> by CLEAR, a cannabis reform advocacy group. The paper lays out a detailed framework for the UK&#8217;s potential cannabis industry, from cultivation to retail.
The report proposes establishing a cannabis inspectorate to oversee commercial cultivation, importation, distribution and taxation. The aim is to create a regulated market similar to <a href="https://www.benzinga.com/general/biotech/24/05/39076458/canadian-cannabis-market-trends-sales-increase-as-youth-impact-study-unfolds">Canada&#8217;s</a>, where after six years, over 70% of all cannabis sales occur through legal channels.
<h3 class="wp-block-heading">Cannabis Market Could Stabilize Illicit Trade</h3>
The piece highlights how <a href="https://www.benzinga.com/topic/cannabis-regulation">cannabis regulation</a> could help control the UK's illicit cannabis market, currently valued between £2.9 billion ($3.84B) and £8.8 billion ($11.67B) per year. By implementing a £1-per-gram cannabis tax ($1.33 dollars), the Treasury could gain substantial revenue while avoiding the pitfalls of over-taxation seen in states like <a href="https://www.benzinga.com/markets/cannabis/24/04/38387994/california-cannabis-industry-is-drowning-in-debt-732m-owed-in-taxes-72-by-companies-already-clos">California</a>, where the illicit market <a href="https://www.benzinga.com/markets/cannabis/24/06/39188435/californias-cartel-cannabis-flourishes-in-national-parks-weed-grown-on-public-lands-accounts-for">continues to thrive</a> despite legalization.
"There isn't really any coherent argument against regulating cannabis," Peter Reynolds, president of CLEAR <a href="https://www.leafie.co.uk/news/cannabis-legalisation-worth-9-billion-uk/">told</a> Leafie. "It will reduce crime, violence, street dealing, underage use and help to prevent children from being dragged into gangs." Reynolds expressed frustration over the lack of political will to address cannabis reform. "The real problem is that our politicians don't have the courage even to discuss it."
<h3 class="wp-block-heading">New Approach To Cannabis Cultivation</h3>
CLEAR's proposal outlines a permissive yet structured approach to home cultivation, suggesting adults should be allowed to grow up to three indoor cannabis plants, plus three more under natural light, or a total of six plants outdoors. The plan also proposes a separate space for cuttings and seedlings. Unlike other countries with more restrictive cultivation laws, the UK could lead in allowing more personal freedom for home growers.
Reynolds further emphasized the economic benefits of legalizing cannabis. "Our proposals are business-friendly," he said. "Get this right, and we can create thousands of new jobs, fight crime and protect children. When will our politicians wake up?"
<h3 class="wp-block-heading">Potential Social And Health Benefits</h3>
Beyond economic gains, regulation could lead to significant public health benefits. The report cites studies showing that <a href="https://www.benzinga.com/markets/cannabis/24/05/38952528/cannabis-legalization-22m-us-teenagers-are-less-interested-in-weed-in-states-where-its-legal-go-">cannabis regulation reduces teen use</a>, lowers alcohol and cigarette consumption and decreases opioid-related deaths. An estimated 1.5 to 2.7 million people in the UK use cannabis monthly, with about 10 million having used it in the past year. Regulation would provide a safer environment for this significant portion of the population. However, the report also cautions against over-taxation.
The California model is often cited as an example of how high tax rates can drive consumers back to illicit markets. Instead, CLEAR points to <a href="https://www.benzinga.com/topic/canada-cannabis">Canada</a> as a model for success, where government regulation has been more effective in curbing illegal sales and maintaining price stability.
Cover image made with AI

Cannabis

Retail Sales

UK Could Net Up To $12.6B Annually From Cannabis Legalization

Wells Fargo analyst Matthew Akers maintains Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) with a Underweight and lowers the price target from $119 to $110.

Wells Fargo Maintains Underweight on Boeing, Lowers Price Target to $110

iShares MSCI Israel Capped Investable Market Index Fund

ISRA

Pentagon Says U.S. Fully Supports Israel's Right To Defend Itself After Iran's "Significant" Attack

Wells Fargo analyst Matthew Akers maintains Booz Allen Hamilton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) with a Overweight and raises the price target from $165 to $185.

Wells Fargo Maintains Overweight on Booz Allen Hamilton, Raises Price Target to $185

Macro Notification

General

U.S. State Department Says Israel Has The Right To Defend Itself, But We Will Coordinate With Them On What Any Response Looks Like

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock&#39;s price, but are they really important?
Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let&#39;s see what these Wall Street heavyweights think about Arista Networks (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/anet#NYSE">ANET</a>).
Arista Networks currently has an average brokerage recommendation of 1.67, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 23 brokerage firms. An ABR of 1.67 approximates between Strong Buy and Buy.
Of the 23 recommendations that derive the current ABR, 15 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 65.2% and 8.7% of all recommendations.
<h2>Brokerage Recommendation Trends for ANET</h2>
<img alt="Broker Rating Breakdown Chart for ANET" class="chart" src="https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/ANET_10012024.png" style="width:100%" title="" /> 
While the ABR calls for buying Arista Networks, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.
Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five &quot;Strong Buy&quot; recommendations for every &quot;Strong Sell&quot; recommendation.
In other words, their interests aren&#39;t always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock&#39;s price movement.
Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock&#39;s price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.
<h2>ABR Should Not Be Confused With Zacks Rank</h2>
Although both Zacks Rank and ABR are displayed in a range of 1-5, they are different measures altogether.
The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers&#39; vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.
In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.
In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.
There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.
<h2>Is ANET a Good Investment?</h2>
In terms of earnings estimate revisions for Arista Networks, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $8.24.
Analysts&#39; steady views regarding the company&#39;s earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Arista Networks.
It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Arista Networks.
<a href="https://www.zacks.com/stock/news/2343971/wall-street-analysts-think-arista-networks-anet-is-a-good-investment-is-it?cid=CS-BENZ-FT-fundamental_analysis|average_broker_rating-2343971">To read this article on Zacks.com click here.</a>

ANET

Wall Street Analysts Think Arista Networks Is a Good Investment: Is It?

AMZN

Amazon Pharmacy Customers Can Have Their Medications Pre-Sorted Into Packets Using New Pillpack Feature

Wells Fargo analyst Matthew Akers maintains CACI International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CACI#NYSE">CACI</a>) with a Overweight and raises the price target from $525 to $577.

CACI

Wells Fargo Maintains Overweight on CACI International, Raises Price Target to $577

Pentagon Says We Condemn These Reckless Attacks By Iran And Call On Iran To Halt Further Attacks, Including By Proxy Forces; U.S. Navy Destroyers Fired About A Dozen Interceptors Against Iranian Missiles Headed To Israel; Not Aware Of Any Warning By Iran Ahead Of Attack On Israel; No Other U.S. Military Assets, Beyond The Navy Destroyers, Helped Shoot Down Iranian Missiles, All Of Which Were Fired From Inside Iran

Wells Fargo analyst Matthew Akers maintains Leidos Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>) with a Overweight and raises the price target from $172 to $183.

LDOS

Wells Fargo Maintains Overweight on Leidos Holdings, Raises Price Target to $183

Many investors are going full macro mode right now, focusing too much on today&#39;s data and not on tomorrow&#39;s implications. The U.S. election is coming up in a little over a month, a new earnings season is underway, and lots of economic data is pending for the Federal Reserve (the Fed) to consider further interest rate cuts before 2024 is over.
So far, the path is set for more rate cuts, with other countries starting to follow this same view, China being the latest to cut by 50 basis points last week. Some are still pointing to economic data like unemployment and contracting manufacturing PMI index readings for the past 22 months to quote a &lsquo;hard landing,&#39; but sticking to this view might keep these investors 100% bearish and potentially miss out on some of the potential rallies that can still be had.
One potential rally can be found in shares of Salesforce Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/crm#NYSE">CRM</a>), especially now that Wall Street has reiterated a new boost on the stock&#39;s price target, pointing to further upside in the coming quarters. The reason behind the boost is exactly what retail investors should focus on in their portfolio strategy, and it has to do with the economy and business model for cloud businesses in the technology sector.
<h2>What If the Bears Are Right? What Happens to Salesforce Stock?</h2>
A bearish scenario for the S&amp;P 500 doesn&#39;t have to mean a bearish scenario for all stocks. If the bearish scenario plays out, unemployment might keep heading higher, and businesses will have to look for alternatives in hiring and managing their workforce today.
This is where Salesforce stock comes into play. As a cloud-based platform, Salesforce can streamline and improve most business processes in today&#39;s economy. This means cost savings and increased efficiency for its customers. So, if unemployment is on the rise in this bearish scenario, businesses can keep expensive employees on payroll or adjust for the slowdown by implementing technology.
Salesforce stock bulls can now understand where new demand will come from, but the rest of the business model is what will deliver the stability and predictability that helped Wall Street analysts land a higher price target. Cloud service businesses like Salesforce, Adobe Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adbe#NASDAQ">ADBE</a>), and Workday Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wday#NASDAQ">WDAY</a>) all operate under a subscription model, which can be critical during a hard landing.
Why? Subscriptions provide more predictable and stable cash flows for the companies that receive them, making projections and valuations easier to calculate despite any uncertainty and volatility in the overall market. That&#39;s for the bearish side, but what if the bulls are right and the market actually does well?
Salesforce also has a bullish scenario at play: Businesses need to use the platform to manage the higher business activity if the economy does manage to pull a &lsquo;soft landing&#39;. Whichever way investors look at Salesforce stock, there is a path for it to move higher, which is why Wall Street analysts felt comfortable boosting it.
<h2>Where Analysts See Salesforce Heading Next</h2>
The consensus price target for Salesforce stock is now set at $308 a share, which calls for a net 11.3% upside from where the stock trades today. Those at Wedbush stand out from the pack, with a recent price boost as recently as last week, setting the valuation up to $325 a share, calling for a much higher 17.5% net upside from today&#39;s price.
Wedbush is not alone, however, as analysts at Piper Sandler agreed on a $325 price target for Salesforce stock last week. This shows investors that the rest of Wall Street sentiment is now shifting to the bullish end for this company, and both economic scenarios seem to back the business model&#39;s predictability and stability for the future.
Even though Salesforce stock trades at 86% of its 52-week high today, there is still much more upside aside from current analyst upgrades. Compared to the rest of the computer sector, Salesforce offers a discount based on several valuation multiples.
On a price-to-earnings (P/E) basis, Salesforce trades at a 49.8x multiple. This current valuation places Salesforce at a 78.5% discount to the computer sector&#39;s average P/E valuation of 232.7x today, creating a path for a potential new 52-week high for Salesforce.
On a price-to-book (P/B) basis, Salesforce trades at a 4.6x valuation compared to the computer sector&#39;s valuation of 7.2x. This shows investors how Salesforce stock could have more room to move higher despite already trading near its 52-week high. The bullishness in the face of this discount didn&#39;t stop on Wall Street, however.
Those at Centaurus Financial decided to boost their holdings in Salesforce stock by 23.4% as recently as September 2024, bringing their net investment up to $3.2 million today. Even the Healthcare of Ontario Pension Plan doubled its holding in September, bringing its net allocation up to $48.1 million to show investors another bullish angle for Salesforce stock.
The article &quot;<a href="https://www.marketbeat.com/stock-ideas/salesforce-stock-gets-a-wall-street-boost-cloud-businesses-back/">Salesforce Stock Gets a Wall Street Boost, Cloud Businesses Back?</a>&quot; first appeared on MarketBeat.

Tech

ADBE

WDAY

Salesforce Stock Gets a Wall Street Boost, Cloud Businesses Back?

The Last Prisoner Project (LPP) marked a milestone in its relentless fight for justice last weekend at Sony Hall in New York City. 
To celebrate the occasion, LPP hosted the Journey to Justice Gala, which brought together a diverse group of advocates, former prisoners and industry leaders.
The gala, an emotional and impactful evening, showcased the human stories behind the fight for cannabis reform. The night's proceeds will support LPP's legal, policy and reentry services, ensuring the continuation of these vital programs. Each table at the gala was named after an LPP constituent. Guests were provided with badges that told the story of those whose lives have been upended by harsh cannabis laws. QR codes on the badges directed attendees to resources and donation platforms, further driving home the urgency of the cause.
<h3 class="wp-block-heading">Advocacy At The Forefront</h3>
Stephanie Shepard, LPP's director of advocacy and a former prisoner herself, opened the event with a deeply personal reflection on her journey. "I was convicted in New York, so it's full circle to be here supporting this cause, when I was supported by so many people in this room," Shepard said, highlighting the powerful community that LPP has built over the years.
Sarah Gersten, LPP's executive director and co-founding member, emphasized the profound impact of the organization's Cannabis Justice Initiative (CJI). "I'm so proud to say that our CJI has represented over 300 clients and reduced over 100 years of prison time for our constituents," Gersten said. Her words resonated even more as she introduced Andy Cox, one of the initiative's success stories. Cox, who had been serving a life sentence for cannabis, was released early thanks to LPP's advocacy. In a moving speech, Cox shared, "If it weren't for LPP and Goodwin, I would still be sitting in a dark and lonely federal prison cell."
<h3 class="wp-block-heading">Free And Still Fighting</h3>
The event also highlighted the importance of public support in driving change. NFL Hall of Famer Calvin "Megatron" Johnson introduced Michael Thompson of Michigan who spent more than two decades behind bars for a nonviolent cannabis sale. National support and LPP's advocacy led to Thompson's clemency in 2021. "They are true fighters. All you gotta do is care, all you gotta do is care," Thompson said passionately.
LPP's co-founding member Mary Bailey took the stage to honor Richard DeLisi, who served 32 years for a nonviolent cannabis offense. DeLisi's story is a symbol of the devastation caused by unjust cannabis laws. Since his release in 2020, DeLisi and his family have been vocal advocates for reform, using their cannabis brand, DeLisioso, to raise funds for LPP and other organizations. Bailey reflected on witnessing DeLisi's reunion with his family. "I will never forget the feeling of watching a family reunite after 32 years."
<h3 class="wp-block-heading">A Call For Clemency And Reform</h3>
Among the event&#8217;s notable moments was a message from Maryland Governor Wes Moore, who praised LPP's &#8216;Pen to Right History&#8217; campaign. The initiative challenges leaders across the U.S. to follow his example by signing executive clemency orders to release individuals incarcerated for cannabis. JoJo Simmons also presented an award to Richeda Sinclair for her advocacy work on behalf of her father, Ricardo Ashmeade, who is currently serving a 22-year sentence for a cannabis offense.
The emotional weight of the evening peaked when LPP's advocacy associate Donte West honored his former prison bunkmate, Kyle Page. Their stories of incarceration and subsequent advocacy reflect the resilience and determination of those still fighting for freedom.
<h3 class="wp-block-heading">A Night Of Unforgettable Performances</h3>
In addition to the inspiring speeches, the gala featured performances that energized the room. Damian and Stephen Marley took the stage for an acoustic medley, including their hit song &#8220;Medication,&#8221; followed by a tribute to their father, Bob Marley, with &#8220;Get Up, Stand Up.&#8221; M-1 and Umi of dead prez performed their iconic track &#8220;Hip-Hop&#8221; and Keith Shocklee of Public Enemy closed the night with a DJ set that kept the crowd dancing.
<h3 class="wp-block-heading">Importance Of Continued Support</h3>
The night was made possible through the generous support of sponsors, including HBI International, makers of RAW rolling papers, which have donated $200,000 to LPP's reentry grant program. Their contributions, along with those of Dutchie, Goodwin, Wana Brand Foundation and others, have enabled LPP to continue its mission to free cannabis prisoners and help them rebuild their lives.
For those unable to attend, LPP continues its work through initiatives like the #Countdown4Clemency campaign, pushing for President Biden to grant clemency to those still imprisoned for cannabis offenses. More information can be found on LPP's website.
Photo Credit: Johnny Nunez/Getty Images for Last Prisoner Project
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

A Gala For Cannabis Justice: Inside The Last Prisoner Project's NYC Event, Featuring Damian And Stephen Marley

White House Says Important That Both Parties In Port Workers' Strike Come To Table And Negotiate In Good Faith; Only Fair That Port Workers See Meaningful Increase In Their Wages; Time For USMX To Negotiate A Fair Contract

Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide

An update from Sagimet Biosciences, Inc. Class A (SGMT) is now available. Sagimet Biosciences Inc. has expanded its Board of Directors, appointing ...

Sagimet Biosciences Expands Board with Two Key Appointments

89bio: Bullish In Light Of Further MOA Being Established By Peer

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Sagimet Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/sgmt-stock-quote/">SGMT</a>) just reported results for the second quarter of 2024.<ul><li>Sagimet Biosciences reported earnings per share of -25 cents. This was above the analyst estimate for EPS of -33 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/sgmt-stock-earnings-sagimet-biosciences-for-q2-of-2024/">SGMT Stock Earnings: Sagimet Biosciences Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

SGMT Stock Earnings: Sagimet Biosciences Beats EPS for Q2 2024

Analyst Ed Arce of H.C. Wainwright maintained a Buy rating on Sagimet Biosciences, Inc. Class A (SGMT – Research Report), retaining the price targe...

Buy Rating Backed by Positive Phase 2b Results and Potential for MASH Backbone Therapy

Sagimet Biosciences GAAP EPS of -$0.25

Sagimet Biosciences files $300M mixed securities shelf

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Liquidia Technologies (LQDA – Research Report) and S...

Analysts Offer Insights on Healthcare Companies: Liquidia Technologies (LQDA) and Sagimet Biosciences, Inc. Class A (SGMT)

Sagimet soars on FDA breakthrough therapy designation for its liver disease treatment

Jonathan Wolleben, an analyst from JMP Securities, reiterated the Buy rating on Sagimet Biosciences, Inc. Class A (SGMT – Research Report). The ass...

Buy Rating Justified: Sagimet Biosciences' Denifanstat Poised to Transform NASH Treatment Landscape

AKRO

ASCLF

ETNB

LQDA

MDGL

SGMT

VKTX

Press Releases

Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Health Care

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024

Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat

Management

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit

Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH

BRNS

RCUS

SNDX

TRVN

ZURA

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

AlloVir

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

BioAtla

Benitec Biopharma

BeyondSpring

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

Cibus

Chimerix

Connect Biopharma Holdings Limited - American Depositary Shares

Connect Biopharma Hldgs

Coya Therapeutics

CytomX Therapeutics

Genelux

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

HilleVax

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

Inventiva S.A. - American Depository Shares

Inventiva

Metagenomi

Ovid Therapeutics

PMV Pharma

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

Vistagen Therapeutics, Inc. - Common Stock

Vistagen Therapeutics

JMP Securities

HC Wainwright & Co.

Goldman Sachs

Leerink Partners

Piper Sandler

Sagimet Biosciences shares are trading higher after the company announced it was granted an FDA Breakthrough Therapy Designation for Denifanstat for noncirrhotic metabolic dysfunction associated steatohepatitis with moderate to advanced liver fibrosis.

Comments

Sagimet Biosciences

Interés en corto

Sagimet Biosciences (NASDAQ:SGMT) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL